Common Drug Review *

Submission Status

Product: Orencia

Generic Name: abatacept

Manufacturer: Bristol-Myers Squibb Canada

Submission Type: Resubmission 1

Date Submission Received: 2009-Dec-02 **Date NOC Issued:** 2006-Jun-29

Targeted CEDAC Meeting: 2010-May-19 **Priority Review Granted:** Not Requested

	Phase	Target Time (Business Days)	Target Date**	Actual CDR Date	Comments
	Submission Assessment	10	2009-Dec-16	2009-Dec-16	
1	Submission deemed complete			2009-Dec-16	Resubmission deemed complete. First resubmission accepted under six-month pilot project for expanded criteria for resubmissions.
2	CDR Reviewers' Reports Completed • Reviewers selected and contracted • Literature search and selection completed • Systematic review of clinical data completed • Critical appraisal of pharmacoeconomic (PE) data completed • Clinical and PE reports written • Reports edited and finalized • Reviewers' reports sent to manufacturer	45	2010-Mar-10	2010-Mar-22	Additional information requested January 7, 2010. Additional information requested January 13, 2010. Additional information received January 18, 2010. Additional information received January 19, 2010. Additional information requested January 21, 2010. Additional information received January 22, 2010. Additional information requested January 26, 2010. Additional information requested February 2, 2010. Additional information received February 4, 2010. Additional information requested February 8, 2010. Additional information received February 16, 2010.
3	Comments from Manufacturer on Reviewers' Reports Received by CDR	7	2010-Mar-19	2010-Mar-31	Due date for manufacturer's comment March 31, 2010.
4	Reviewers' Reply to Manufacturer's Comments Completed	7	2010-Mar-29	2010-Apr-12	Due date for reviewers' April 12, 2010.
5	CEDAC Brief Completed and Sent to CEDAC Members	5	2010-May-05	2010-May-05	
6	CEDAC Meeting		2010-May-19	2010-May-19	
7	CEDAC Recommendation and Reasons for Recommendation Sent to Drug Plans, ACP and Manufacturer	5	2010-May-27	2010-May-27	
8	Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation	10	2010-Jun-10	2010-Jun-10	
9 (a)	Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5	2010-Jun-17	2010-Jun-17	Notice of Final Recommendation issued.
	OR				
9 (b)	Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
	OR				
9 (c)	Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates			
10	Final Recommendation sent to Drug Plans, ACP, and Manufacturer	5			

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.

** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca.

*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.

Reflects updates as of Thursday noon.